CD276 and neoplasm: To address this problem, we designed a bivalent tandem CAR (TanCAR) targeted two pan-tumor-associated antigens, CD70 and B7-H3 (CD276), which could also apply for the immunotherapy of multiple types of solid tumor and melanoma.